Evolving Practice Patterns for Clear Cell Renal Cell Carcinoma
A discussion regarding the potential implications of treating renal cell carcinoma based on recent clinical trial data and key presentations from the 2021 ASCO virtual meeting.
EP. 1: Frontline Treatment Advances in Metastatic RCC
Robert Alter, MD, John Theurer Cancer Center
Dr. Sandy Srinivas comments on treatment approaches for frontline metastatic renal cell carcinoma based on the emergence of novel combination regimens that introduce immunotherapy.
EP. 2: Frontline Metastatic RCC: Nivolumab Plus Ipilimumab
Robert Alter, MD, John Theurer Cancer Center
Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.
EP. 3: Frontline Metastatic RCC: Pembrolizumab Plus Axitinib
Robert Alter, MD, John Theurer Cancer Center
Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.
EP. 4: Frontline Metastatic RCC: Nivolumab Plus Cabozantinib
Robert Alter, MD, John Theurer Cancer Center
Robert S. Alter, MD, provides key takeaways from the CheckMate 9ER study of nivolumab plus cabozantinib as frontline therapy for patients with metastatic renal cell carcinoma.
EP. 5: The CLEAR Trial in Metastatic RCC
Robert Alter, MD, John Theurer Cancer Center
Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.
EP. 6: I-O/TKI Regimens for Metastatic RCC: Dosing Strategies
Robert Alter, MD, John Theurer Cancer Center
Recommendations for dosing targeted therapy-immunotherapy combinations used to treat patients with metastatic renal cell carcinoma.
EP. 7: Intermediate/Poor-Risk mRCC: I-O/I-O Vs I-O/TKI Therapy
Robert Alter, MD, John Theurer Cancer Center
Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.
EP. 9: Favorable-Risk mRCC: When to Initiate Therapy
Robert Alter, MD, John Theurer Cancer Center
Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.
EP. 14: Relapsed/Refractory mRCC: Sequencing Therapy
Robert Alter, MD, John Theurer Cancer Center
Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.
EP. 15: Emerging Therapies for Relapsed/Refractory mRCC
Robert Alter, MD, John Theurer Cancer Center
Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.
EP. 16: Incorporating Treatment Advances Into mRCC Management
Robert Alter, MD, John Theurer Cancer Center
Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
